Gedeon Richter has filed a patent for new pyrazolo[1,5-a]pyrimidine derivatives that act as GABAB receptor positive allosteric modulators. The patent also covers the process for producing these compounds, pharmaceutical compositions containing them, and their use in treating diseases mediated by the GABAB receptor positive allosteric mechanism. GlobalData’s report on Gedeon Richter gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Gedeon Richter, Human telomerase RT biomarker was a key innovation area identified from patents. Gedeon Richter's grant share as of September 2023 was 65%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230286988A1) describes a compound of formula (I) and its various applications in the field of medicine. The compound has potential as a GABAB receptor positive allosteric modulator, which means it can enhance the activity of this receptor in the body. The patent claims cover the compound itself, as well as its pharmaceutical compositions, combinations with other therapeutic agents, and methods of manufacturing and using the compound.
The compound of formula (I) is described as having different substituents represented by X and Z. The patent claims specify various possibilities for X and Z, including different functional groups and chemical structures. The compound can be used in the treatment or prevention of disorders associated with GABAB receptor positive allosteric modulator activity. These disorders include psychiatric disorders (such as anxiety, depression, and schizophrenia), neurodevelopmental disorders (such as autism spectrum disorder and Fragile X syndrome), cognitive disorders, epilepsy, spasticity, skeletal muscle rigidity, and many others.
The patent claims also cover the use of the compound as an intermediate in the synthesis of other compounds of interest. These intermediates can be useful in the production of the compound of formula (I) or related compounds.
Overall, this patent describes a compound with potential therapeutic applications in a wide range of disorders associated with GABAB receptor positive allosteric modulator activity. The patent claims cover the compound itself, its pharmaceutical compositions, combinations with other therapeutic agents, and methods of manufacturing and using the compound. Further research and development may be needed to fully explore the potential of this compound in the field of medicine.
To know more about GlobalData’s detailed insights on Gedeon Richter, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
